Literature DB >> 1706665

Reduction of peripheral blood macrophages/monocytes in Kawasaki disease by intravenous gammaglobulin.

S Furukawa1, T Matsubara, K Jujoh, K Sasai, S Nakachi, T Sugawara, K Yabuta, H Kato.   

Abstract

The effects of intravenous gammaglobulin (IVGG) on changes in the peripheral blood mononuclear cell subsets during acute Kawasaki disease (KD) were studied by a random selection trial of IVGG plus Aspirin (group G) compared to Aspirin alone (group A). Group G received IVGG with 200 mg/kg per day x 5 dose. The absolute counts of peripheral blood mononuclear cell subsets were assayed by a fluorescence-activated cell sorter using monoclonal antibodies of Leu series. Before therapy, patients in each treatment group had increased counts of CD14 + macrophage/monocytes compared to healthy childhood controls (P less than 0.01). After IVGG treatment group G underwent a greater decrease in their CD14 + macrophage/monocyte counts (P less than 0.01) than group A. The changes of CD3+ T cells. Leu 7+ NK/K cells and CD19+ B cells in the peripheral blood mononuclear cell subsets with treatment in group G, were similar to those in group A. These results suggest the possibility that IVGG therapy is effective in KD by modulating macrophages/monocytes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1706665     DOI: 10.1007/bf01959479

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  19 in total

1.  The treatment of Kawasaki syndrome with intravenous gamma globulin.

Authors:  J W Newburger; M Takahashi; J C Burns; A S Beiser; K J Chung; C E Duffy; M P Glode; W H Mason; V Reddy; S P Sanders
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

2.  Immunopathology of the skin lesion of Kawasaki disease.

Authors:  T Sugawara; S Hattori; S Hirose; S Furukawa; K Yabuta; T Shirai
Journal:  Prog Clin Biol Res       Date:  1987

3.  [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

Authors:  T Kawasaki
Journal:  Arerugi       Date:  1967-03

4.  A unique human B lymphocyte antigen defined by a monoclonal antibody.

Authors:  T C Meeker; R A Miller; M P Link; J Bindl; R Warnke; R Levy
Journal:  Hybridoma       Date:  1984

5.  Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells.

Authors:  J S Pober; M P Bevilacqua; D L Mendrick; L A Lapierre; W Fiers; M A Gimbrone
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

6.  Pathology of the heart in Kawasaki disease.

Authors:  H Fujiwara; Y Hamashima
Journal:  Pediatrics       Date:  1978-01       Impact factor: 7.124

7.  Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin.

Authors:  D Y Leung; J C Burns; J W Newburger; R S Geha
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

8.  High-dose intravenous gammaglobulin for Kawasaki disease.

Authors:  K Furusho; T Kamiya; H Nakano; N Kiyosawa; K Shinomiya; T Hayashidera; T Tamura; O Hirose; Y Manabe; T Yokoyama
Journal:  Lancet       Date:  1984-11-10       Impact factor: 79.321

9.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor.

Authors:  P P Nawroth; D M Stern
Journal:  J Exp Med       Date:  1986-03-01       Impact factor: 14.307

10.  Antibodies to membrane structures that distinguish suppressor/cytotoxic and helper T lymphocyte subpopulations block the mixed leukocyte reaction in man.

Authors:  E G Engleman; C J Benike; E Glickman; R L Evans
Journal:  J Exp Med       Date:  1981-07-01       Impact factor: 14.307

View more
  9 in total

Review 1.  Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease.

Authors:  T Matsubara; T Ichiyama; S Furukawa
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

2.  Serum soluble CD4 and CD8 levels in Kawasaki disease.

Authors:  S Furukawa; T Matsubara; K Tsuji; T Motohashi; K Okumura; K Yabuta
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

3.  Anti-inflammatory effect of intravenous immunoglobulin in comparison with dexamethasone in vitro: implication for treatment of Kawasaki disease.

Authors:  Haruyuki Makata; Takashi Ichiyama; Ryutaro Uchi; Tsuyoshi Takekawa; Tomoyo Matsubara; Susumu Furukawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-08-01       Impact factor: 3.000

4.  Serum resistin concentrations in children with Kawasaki disease.

Authors:  Hiroki Nozue; Hironori Imai; Hisako Saitoh; Takeshi Aoki; Kunio Ichikawa; Tomohiro Kamoda
Journal:  Inflamm Res       Date:  2010-04-27       Impact factor: 4.575

5.  Intravenous immunoglobulin inhibits NF-kappaB activation and affects Fcgamma receptor expression in monocytes/macrophages.

Authors:  Takashi Ichiyama; Yoshiko Ueno; Masanari Hasegawa; Akihiro Niimi; Tomoyo Matsubara; Susumu Furukawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-25       Impact factor: 3.000

6.  The "Intermediate" CD14 + CD16 + monocyte subpopulation plays a role in IVIG responsiveness of children with Kawasaki disease.

Authors:  Yi Seul Kim; Hyun Jin Yang; Seung-Jung Kee; Insu Choi; Kisoo Ha; Katrina K Ki; In Seok Jeong; Hwa Jin Cho
Journal:  Pediatr Rheumatol Online J       Date:  2021-05-31       Impact factor: 3.054

7.  Variation in IL-21-secreting circulating follicular helper T cells in Kawasaki disease.

Authors:  Meng Xu; Yanfang Jiang; Jian Zhang; Yan Zheng; Deying Liu; Lishuang Guo; Sirui Yang
Journal:  BMC Immunol       Date:  2018-12-27       Impact factor: 3.615

8.  Circulating Immune Cell Profile and Changes in Intravenous Immunoglobulin Responsiveness Over the Disease Course in Children With Kawasaki Disease.

Authors:  In Su Choi; Mi Ji Lee; Seul A Choi; Kyung Soon Choi; In Seok Jeong; Hwa Jin Cho
Journal:  Front Pediatr       Date:  2022-02-04       Impact factor: 3.418

Review 9.  Current perspectives on Kawasaki disease.

Authors:  Monesha Gupta-Malhotra; P Syamasundar Rao
Journal:  Indian J Pediatr       Date:  2005-07       Impact factor: 1.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.